卡培他滨与替吉奥治疗晚期胃癌一线诱导化疗后维持的效果分析

Effect Analysis of Capecitabine and Tegafur,Gimeracil and Oteracil Potassium as Maintenance Therapy of Advanced Gastric Cancer After First-Line Induction Chemotherapy

目的:探讨卡培他滨与替吉奥治疗晚期胃癌一线诱导化疗后维持的效果。方法:选取2018年1月—2021年4月沂水县人民医院收治的晚期胃癌一线诱导化疗后患者80例作为研究对象,以随机数字表法分为观察1组和观察2组,各40例。观察1组采用卡培他滨维持治疗,观察2组采用替吉奥维持治疗,选取同期单纯化疗患者40例设为单纯化疗组。比较三组治疗结果、疾病进展期、生存期、不良反应发生情况、生活质量评分。结果:观察1组与观察2组治疗总缓解率、疾病进展期、生存期以及情感、生理功能、身体疼痛、社会功能、精神、活动、心理、总健康评分比较,差异无统计学意义(P>0.05);观察1组、观察2组治疗总缓解率、生活质量各指标评分均高于单纯化疗组,疾病进展期均短于单纯化疗组,生存期均长于单纯化疗组,差异有统计学意义(P<0.05);三组疲惫乏力、胃肠道反应、口腔炎、手足综合征、贫血发生率比较,差异无统计学意义(P>0.05)。结论:卡培他滨与替吉奥治疗晚期胃癌一线诱导化疗后维持的效果相当,均可延长患者生存期,控制肿瘤进展,改善患者生活质量,且不会增加不良反应发生率。

Objective:To investigate the effect of Capecitabine and Tegafur,Gimeracil and Oteracil Potassium as maintenancetherapy of advanced gastric cancer after first-line induction chemotherapy.Methods:A total of 80 patients with advanced gastriccancer treated in Yishui County People's Hospital from January 2018 to April 2021 after first-line induction chemotherapy wereselected as the study subjects.They were divided into observation group 1 and observation group 2 by random number tablemethod,with 40 cases in each group.The observation group 1 was treated with Capecitabine maintenance therapy,and the obser-vation group 2 was treated with Tegafur,Gimeracil and Oteracil Potassium maintenance therapy.During the same period,40 pa-tients treated with chemotherapy alone were selected as chemotherapy alone group.The treatment outcome,time to disease pro-gression,survival time,adverse reactions and quality of life score of the three groups were compared.Results:There were no sig-nificant differences between the observation group 1 and the observation group 2 in the total response rate,time to disease progres-sion,survival time,emotion,physiological function,physical pain,social function,mental health,vitality,psychological functionand total health scores(P>0.05).The total response rate and quality of life scores in the observation group 1 and the observationgroup 2 were higher than those in chemotherapy alone group,and the time to disease progression was shorter than that in chemo-therapy alone group,and the survival time was longer than that in chemotherapy alone group,and the difference was statisticallysignificant(P<0.05).There were no significant differences in the incidence of fatigue,gastrointestinal reactions,stomatitis,hand-foot syndrome and anemia among the three groups(P>0.05).Conclusion:Capecitabine and Tegafur,Gimeracil and Oteracil Potas-sium are equivalent as maintenance therapy of advanced gastric cancer after first-line induction chemotherapy,both of which canprolong the survival time of patients,control tumor progression,improve the quality of life,and will not increase the incidence ofadverse reactions.